Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation

Biol Blood Marrow Transplant. 2010 Apr;16(4):555-9. doi: 10.1016/j.bbmt.2009.12.004. Epub 2010 Jan 29.

Abstract

Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received induction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimen was melphalan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4 subsequently relapsed. After a median follow-up of 31 months, 6 patients (49%) survived long term. Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT.

MeSH terms

  • Aged
  • Cell Transformation, Neoplastic
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Leukemia / pathology
  • Leukemia / therapy*
  • Male
  • Melphalan / administration & dosage
  • Melphalan / therapeutic use
  • Middle Aged
  • Primary Myelofibrosis / pathology
  • Primary Myelofibrosis / therapy*
  • Prognosis
  • Transplantation Conditioning
  • Treatment Outcome

Substances

  • Melphalan